AMSBIO, a provider of cutting-edge life science technologies and services for accelerating discovery in cancer research, has continued its sponsorship of the annual poster prize at the Beatson International Cancer Conference (7th -10th July 2013).

The two winners of the Poster Prize for the best presented and most interesting posters, were this year named as Dr Thomas R Cox and co-researchers** for their work on ‘Deep proteomic analysis of the hypoxic secretome lysyl oxidase as a critical mediator of metastatic lesion formation in bone’, and Dr Jean Albrengues & co-researchers*** for their work on ‘Production of LIF cytokine by cancer cells and fibroblasts contributes to the establishment of a pro-invasive tumour microenvironment’.

As one of Cancer Research UK’s core-funded institutes - the Beatson Institute carries out a programme of world-class science directed at understanding key aspects of cancer cell behaviour, and try to translate these discoveries into new therapies and diagnostic/prognostic tools to help cancer patients. The Institute benefits from close interactions with the University of Glasgow, including strong links with the University’s Institute of Cancer Sciences.

AMSBIO is a rapidly growing company focused on the supply and development of products and technology for cancer research with emphasise on apoptosis, DNA damage and repair, and cancer cell function and behavior. AMSBIO supplies focused research products for cancer research that allow researchers to study cancer cell function and behavior including in angiogenesis, cell invasion and PARP and PARG research. Together with specifically designing assays for lead compound and genotoxic screening based on DNA damage and repair and cancer cell behavior, AMSBIO is establishing itself as a leading international provider of cancer research tools and services.

more about annual poster prize

more about Beatson Institue

About AMS

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. The AMSBIO range includes specialist antibodies, peptides and recombinant proteins. In addition the company is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as experts in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance screening outcomes and eventual prognosis. With a range of molecular detection reagents, and a significant Biorepository the company can also provide tissue DNA, RNA, protein and microarray products. Key research areas for these products include: Oncology, Regenerative Medicine, Environmental Analysis, Cytotoxicity Screening, Glycomics and Stem Cell Biology.more about AMSBIO

more about AMSBIO

more news from AMSBIO